MedTrace Logo

A Study of Buntanetap in Participants With PD

NCT07284784 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 500

Last updated 2026-04-30

No results posted yet for this study

Summary

This study will examine the long-term safety of buntanetap in participants with PD. This will be a 36-month open-label safety study. This study will be conducted with two cohorts. Cohort 1 will enroll via invitation only for PD participants who have previously participated in buntanetap clinical trials. Cohort 2 will be for PD participants who are receiving deep brain stimulation (DBS) treatment. Qualified participants will receive buntanetap 30mg QD after a screening period of up to 42 days.

Conditions

  • Parkinson's Disease (PD)
  • Deep Brain Stimulation

Interventions

DRUG

buntanetap/posiphen

buntanetap capsules 30 mg by mouth daily

Sponsors & Collaborators

  • Duke Clinical Research Institute

    collaborator OTHER

  • Annovis Bio Inc.

    lead INDUSTRY

Principal Investigators

  • Laurie Sanders, Ph.D. · Duke Clinical Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-09
Primary Completion
2029-09-30
Completion
2029-11-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07284784 on ClinicalTrials.gov